Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note released on Friday morning. The brokerage issued a sell rating on the stock.

A number of other research analysts also recently weighed in on SYRS. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Stock Up 2.2 %

SYRS opened at $0.21 on Friday. Syros Pharmaceuticals has a one year low of $0.18 and a one year high of $7.96. The business has a 50 day simple moving average of $0.23 and a two-hundred day simple moving average of $2.00.

Syros Pharmaceuticals (NASDAQ:SYRS) last announced its earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the prior year, the company posted ($1.35) EPS. Research analysts anticipate that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insiders Place Their Bets

In related news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the transaction, the director now directly owns 41,070 shares in the company, valued at $11,088.90. The trade was a 76.64 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 12.26% of the company’s stock.

Institutional Trading of Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. GSA Capital Partners LLP bought a new stake in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned about 0.06% of Syros Pharmaceuticals at the end of the most recent quarter. 91.47% of the stock is currently owned by institutional investors.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.